Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy

被引:15
作者
Foster, AE
Gottlieb, DJ
Marangolo, M
Bartlett, A
Li, YC
Barton, GW
Romagnoli, JA
Bradstock, KF [1 ]
机构
[1] Westmead Hosp, Blood & Marrow Transplant Serv, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2006, Australia
[3] Univ Sydney, Dept Med, Sydney, NSW 2006, Australia
[4] Univ Sydney, Dept Chem Engn, Sydney, NSW 2006, Australia
来源
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH | 2003年 / 12卷 / 01期
关键词
D O I
10.1089/152581603321210172
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adoptive transfer of donor-derived cytomegalovirus (CMV)-specific cytotoxic T cell (CTL) clones can restore immunity in allogeneic stem cell transplant recipients, providing protection against CMV disease. Current methods for selecting and expanding CMV-specific T cell clones are technically difficult, making adoptive T cell therapy impractical for routine clinical use. In this study, we describe a method for ex vivo generation and expansion of high-purity CMV-specific CTL using peptide-pulsed dendritic cells as antigen-presenting cells. Generation of CMV-specific CTL in numbers sufficient for clinical use in the time span of 4 weeks was accomplished in 6 of 8 CMV-seropositive donors. Examination of pp65 specificity by HLA/peptide tetramer staining demonstrated that a purity of greater than 95% peptide-specific cells could be obtained after two weekly stimulations and retained after further expansion for 3-4 weeks. Median expansion of total cell number was greater than 500-fold and expansion of peptide-specific CTL by tetramer staining was greater than 1.7x10(5)-fold. Four weeks after initiating CTL culture, we were able to generate greater than 109 total cells that specifically lysed target cells loaded with CMV peptide and cells infected with CMV. This simple and rapid method for generating high-purity CMV-specific CTL for adoptive immunotherapy is currently being examined for routine clinical use for allogeneic stem cell transplantation.
引用
收藏
页码:93 / 105
页数:13
相关论文
共 44 条
[1]   Phenotypic analysis of antigen-specific T lymphocytes [J].
Altman, JD ;
Moss, PAH ;
Goulder, PJR ;
Barouch, DH ;
McHeyzerWilliams, MG ;
Bell, JI ;
McMichael, AJ ;
Davis, MM .
SCIENCE, 1996, 274 (5284) :94-96
[2]   Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [J].
Boeckh, M ;
Bowden, RA ;
Gooley, T ;
Myerson, D ;
Corey, L .
BLOOD, 1999, 93 (05) :1781-1782
[3]   Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study [J].
Boeckh, M ;
Gooley, TA ;
Myerson, D ;
Cunningham, T ;
Schoch, G ;
Bowden, RA .
BLOOD, 1996, 88 (10) :4063-4071
[4]   HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - RELATIVE FREQUENCY OF STAGE-SPECIFIC CTL RECOGNIZING THE 72-KD IMMEDIATE EARLY PROTEIN AND GLYCOPROTEIN-B EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
BORYSIEWICZ, LK ;
HICKLING, JK ;
GRAHAM, S ;
SINCLAIR, J ;
CRANAGE, MP ;
SMITH, GL ;
SISSONS, JGP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :919-931
[5]   Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation [J].
Broers, AEC ;
van der Holt, R ;
van Esser, JWJ ;
Gratama, JW ;
Henzen-Logmans, S ;
Kuenen-Boumeester, V ;
Löwenberg, B ;
Cornelissen, JJ .
BLOOD, 2000, 95 (07) :2240-2245
[6]  
Chmielowski B, 1999, J IMMUNOL, V162, P95
[7]   Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection [J].
Diamond, DJ ;
York, J ;
Sun, JY ;
Wright, CL ;
Forman, SJ .
BLOOD, 1997, 90 (05) :1751-1767
[8]  
EINSELE H, 1995, BLOOD, V86, P2815
[9]   Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors [J].
Gillespie, GMA ;
Wills, MR ;
Appay, V ;
O'Callaghan, C ;
Murphy, M ;
Smith, N ;
Sissons, P ;
Rowland-Jones, S ;
Bell, JI ;
Moss, PAH .
JOURNAL OF VIROLOGY, 2000, 74 (17) :8140-8150
[10]   GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT [J].
GOODRICH, JM ;
BOWDEN, RA ;
FISHER, L ;
KELLER, C ;
SCHOCH, G ;
MEYERS, JD .
ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :173-178